Breaking Health News: Abortion Laws, Drug Trials, and Industry Investments

This summary covers key updates in health news: Utah's top court's stance on abortion bans, Eli Lilly's weight-loss drug trial results and shortage resolution, Sanofi's major investment in insulin production, Biogen's profit forecast, Church & Dwight's cautious forecast, Adaptimmune's new cancer therapy approval, ResMed's steady demand for sleep apnea devices, and Novo Nordisk's weight-loss drug launch in Australia.

In a significant decision, Utah's highest court has refused to allow the enforcement of a near-total abortion ban pending a lower court's consideration of Planned Parenthood's challenge. Judge Andrew Stone's earlier block on the law will remain while the case addresses constitutional concerns.

Pharmaceutical giant Eli Lilly reports promising trial results for its weight-loss drug Zepbound, showing a 38% reduction in heart failure risks for obese patients. Additionally, CEO David Ricks confirmed that the drug shortage in the U.S. is expected to end soon, improving access to Mounjaro and Zepbound.

Sanofi announced a €1.3 billion investment in a new insulin production facility in Frankfurt, aiming for completion by 2029. This is a strategic move to enhance their capacity and replace the existing plant in Hoechst.

(With inputs from agencies.)